Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)

被引：21
|
作者：
Barroso-Sousa, Romualdo
Li, Tianyu
Reddy, Sangeetha
Emens, Leisha A.
Overmoyer, Beth
Lange, Paulina
Dilullo, Molly K.
Attaya, Victoria
Kimmel, Jeffrey
Winer, Eric P.
Mittendorf, Elizabeth A.
Tayob, Nabihah
Tolaney, Sara M.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-GS2-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS2-10
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
    Dhakal, Ajay
    O'Regan, Ruth
    Falkson, Carla
    Hicks, David
    Hawkins, Douglas
    Turner, Bradley
    Mohile, Nimish
    CANCER RESEARCH, 2023, 83 (05)
  • [42] Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Efficacy results of a phase II trial (AGMT MBC-6).
    Rinnerthaler, Gabriel
    Gampenrieder, Simon Peter
    Voskova, Daniela
    Petzer, Andreas L.
    Hubalek, Michael
    Petru, Edgar
    Hartmann, Bernd
    Andel, Johannes
    Balic, Marija
    Ulmer, Hanno
    Melchardt, Thomas
    Mlineritsch, Brigitte
    Greil, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer
    Anampa, Jesus
    Chen, Alice
    Wright, John
    Patel, Margi
    Pellegrino, Christine
    Fehn, Karen
    Sparano, Joseph A.
    Andreopoulou, Eleni
    CLINICAL BREAST CANCER, 2018, 18 (01) : E135 - E142
  • [44] Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
    Pernas, Sonia
    Martin, Miguel
    Kaufman, Peter A.
    Gil-Martin, Marta
    Gomez Pardo, Patricia
    Lopez-Tarruella, Sara
    Manso, Luis
    Ciruelos, Eva
    Alejandro Perez-Fidalgo, Jose
    Hernando, Cristina
    Ademuyiwa, Foluso O.
    Weilbaecher, Katherine
    Mayer, Ingrid
    Pluard, Timothy J.
    Martinez Garcia, Maria
    Vahdat, Linda
    Perez-Garcia, Jose
    Wach, Achim
    Barker, Debra
    Fung, Samson
    Romagnoli, Barbara
    Cortes, Javier
    LANCET ONCOLOGY, 2018, 19 (06): : 812 - 824
  • [45] Lapatinib and paclitaxel in HER2-negative, extracellular domain (ECD) positive metastatic breast cancer (MBC) in a randomized phase III study
    Finn, R. S.
    Gagnon, R.
    Di Leo, A.
    Press, M. F.
    Arbushites, M.
    Koehler, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] A retrospective comparison of eribulin and capecitabine in patients with HER2-negative metastatic breast cancer
    Tsushita, N.
    Shimoi, T.
    Okuma, H. S.
    Kawachi, A.
    Kitano, A.
    Nishikawa, T.
    Shimomura, A.
    Noguchi, E.
    Kodaira, M.
    Yunokawa, M.
    Yonemori, K.
    Shimizu, C.
    Fujiwara, Y.
    Tamura, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] Activating HER2 missense mutations in HER2-negative metastatic breast cancer
    Shah, Mirat
    Ensminger, Jennifer
    Wang, Chenguang
    Ali, Siraj
    Chung, Jon
    Lauring, Josh
    Park, Ben Ho
    Stearns, Vered
    CANCER RESEARCH, 2020, 80 (04)
  • [48] New ASCO Guideline on HER2-negative metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03)
  • [49] CIRG/TORI 010: first analysis of a randomized phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer (MBC)
    Martin, M.
    Hurvitz, S.
    Kennedy, J.
    Forbes, J.
    Roche, H.
    Pinter, T.
    Eiermann, W.
    Buyse, M.
    Rupin, M.
    Mackey, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 260 - 260
  • [50] Bevacizumab in HER2-negative non-metastatic breast cancer
    Bennet, Neil
    LANCET ONCOLOGY, 2012, 13 (03): : E93 - E93
12345